An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes
NCT ID: NCT07276776
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2025-12-12
2026-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental- Participants with Type 2 diabetes
Omnipod M system
The Omnipod M system will allow user to use a lower glucose target and improve systems glucose control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Omnipod M system
The Omnipod M system will allow user to use a lower glucose target and improve systems glucose control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening
3. On current insulin regimen for at least 3 months prior to screening (i.e. basal-bolus, basal insulin only or premix)
4. Basal-bolus (AID or non-AID pump \& MDI) or premix users with A1C \< 14% OR basal users on long or intermediate acting insulin only with A1C \> 8.0% and \< 14%
5. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic equivalents
6. Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
7. If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes.
8. Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol
9. Willing to wear the system, including Pods, continuously throughout the study
10. Willing and able to sign the Informed Consent Form (ICF)
11. Able to read and understand English
12. If of childbearing potential, willing and able to have pregnancy testing
Exclusion Criteria
2. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
3. Any planned surgery during the study which could be considered major in the opinion of the Investigator
4. History of more than 1 severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions
5. History of more than 1 diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
6. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
7. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c
8. Use of hydroxyurea
9. Plans to receive blood transfusion over the course of the study
10. Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal).
11. Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study
12. Participation in another clinical study using an investigational drug or device within 30-days or intends to participate in any other study during this study period
13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
14. Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insulet Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Joslin Diabetes
Boston, Massachusetts, United States
MassResearch LLC.
Waltham, Massachusetts, United States
Henry Ford Health
Detroit, Michigan, United States
Mountain Area Health Educational Center ( MAHEC)
Asheville, North Carolina, United States
Texas Diabetes and Endocrinology (TDE)
Austin, Texas, United States
Disease & Glandular Disease Clinic
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Louise Ambler-Osborn
Role: primary
Elizabeth Taylor
Role: primary
Terra Cushman
Role: primary
Michelle Chapman
Role: primary
Jennifer Perez
Role: primary
Terri Ryan
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Evolution 3
Identifier Type: -
Identifier Source: org_study_id